Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any congenital myasthenic syndrome in which the cause of the disease is a mutation in the SYT2 gene.
Features include always present findings: Areflexia; and very common findings: Decreased compound muscle action potential amplitude and Hammertoe. 17 total HPO annotations.
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 5 | Compound muscle action potential amplitude facilitation, Distal muscle weakness, Decreased compound muscle action potential amplitude |
Brain and nerves | 2 | Hyporeflexia, Waddling gait |
Ears | 1 | Hearing loss (hearing impairment) |
Arms and legs | 1 | Foot dorsiflexor weakness |
SYT2 function has not been fully characterized.
Congenital myasthenic syndrome 7 has been associated with mutations in the SYT2 gene on chromosome 1.
Genetic testing for SYT2 is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for congenital myasthenic syndrome 7 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 2 very common features, 8 common features.
No clinical trials have been registered for congenital myasthenic syndrome 7.
22 publications have been identified in PubMed for congenital myasthenic syndrome 7. Research spans Review / Meta-Analysis (32%), Case Report / Case Series (27%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 7 | 32% |
Patient case studies | 6 | 27% |
Disease patterns and progression | 4 | 18% |
Testing and diagnosis research | 3 | 14% |
Clinical study results | 1 | 5% |
New treatment approaches | 1 | 5% |
Ostojić S (2026). [PMID: 42123532](https://pubmed.ncbi.nlm.nih.gov/42123532/). *Int J Mol Sci*. [Diagnostic / Biomarker]
Gill H (2026). [PMID: 41838965](https://pubmed.ncbi.nlm.nih.gov/41838965/). *Neurology*. [Case Report / Case Series]
Garg M (2026). [PMID: 41817069](https://pubmed.ncbi.nlm.nih.gov/41817069/). *Neurol India*. [Epidemiology / Natural History]
Takhman M (2025). [PMID: 41382066](https://pubmed.ncbi.nlm.nih.gov/41382066/). *BMC Neurol*. [Review / Meta-Analysis]
Cossins J (2025). [PMID: 39944742](https://pubmed.ncbi.nlm.nih.gov/39944742/). *Brain Commun*. [Clinical Trial Publication]
Della Marina A (2025). [PMID: 39948634](https://pubmed.ncbi.nlm.nih.gov/39948634/). *Acta Neuropathol Commun*. [Diagnostic / Biomarker]
Abdullah A (2025). [PMID: 40751639](https://pubmed.ncbi.nlm.nih.gov/40751639/). *J Pak Med Assoc*. [Case Report / Case Series]
Fontana PN (2025). [PMID: 41331967](https://pubmed.ncbi.nlm.nih.gov/41331967/). *J Clin Neuromuscul Dis*. [Review / Meta-Analysis]
Kulsirichawaroj P (2025). [PMID: 40494860](https://pubmed.ncbi.nlm.nih.gov/40494860/). *Pediatr Res*. [Diagnostic / Biomarker]
Finsterer J (2025). [PMID: 40330390](https://pubmed.ncbi.nlm.nih.gov/40330390/). *Cureus*. [Case Report / Case Series]